CPP (Cancer Prevention Pharmaceuticals) Liabilities-to-Assets : 3.49 (As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Cancer Prevention Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2016 was $32.04 Mil. Cancer Prevention Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2016 was $9.19 Mil. Therefore, Cancer Prevention Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2016 was 3.49.

Cancer Prevention Pharmaceuticals Liabilities-to-Assets Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Liabilities-to-Assets Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Liabilities-to-Assets

6.06

4.28

12.45

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Liabilities-to-Assets	Get a 7-Day Free Trial			4.28	-	7.02	12.45	3.49

Competitive Comparison of Cancer Prevention Pharmaceuticals's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Liabilities-to-Assets falls into.

Save Embed

;

Save Embed

;

Cancer Prevention Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Cancer Prevention Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2015 is calculated as:

Liabilities-to-Assets (A: Dec. 2015 )	=	Total Liabilities	/	Total Assets
	=	23.032	/	1.85
	=	12.45

Cancer Prevention Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2016 is calculated as

Liabilities-to-Assets (Q: Mar. 2016 )	=	Total Liabilities	/	Total Assets
	=	32.039	/	9.189
	=	3.49

Cancer Prevention Pharmaceuticals (AMEX:CPP) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Cancer Prevention Pharmaceuticals Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Liabilities-to-Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.